Back to results
US 2004/0072743 A1Published application
Pharmaceutical composition of modified pna molecules
OwnerJeppe Viggo Christensen, Edward Kristenseninventors
Life of this patent
Estimating the term…
Abstract
The present invention concerns a pharmaceutical composition for use in combating infections.
Claims12
A pharmaceutical composition comprising a molecule of formula (III):
- PEP-L-A (III)
- wherein
- PEP is any amino acid sequence;
- L is a linker or a bond and
- A is an antisense agent together with at least one pharmaceutically acceptable carrier, binder, thickener, diluent, buffer, preservative, or surface active agent.
2 more elements
A pharmaceutical composition of any of the preceding claims wherein the molecule of formula (III) is selected from the group consisting of:
- 5 (SEQ ID NO:
- 1) H-KFFKFFKFFK-ado-TTC AAA CAT AGT-NH2 (SEQ ID NO:
- 2) H-KFFKFFKFFK-C-smcc-ado-TTC AAA CAT AGT-NH2 (SEQ ID NO:
- 3) H2N-KFFKVKFVVKK-C-smcc-ado-TTC AAA CAT AGT-NH2 (SEQ ID NO:
- 4) H-KFFKFFKFFK-b.cypr-g.abu-ACTTTGTCGCCA-NH2 (SEQ ID NO:
- 5) H-KFFKFFKFFK-achc-b.Ala-TTCTAACATTTA-NH2 (SEQ ID NO:
- 6) H-KFFKFFKFFK-g.abu.PheGly-TTCTAACATTTA-NH2 or (SEQ ID NO:
- 7) H-KFFKFFKFFK-pfPhe-cha-TTCTAACATTTA-NH2.
5 more elements
A pharmaceutical composition according to any of the preceding claims in the form of an oral dosage unit.
A pharmaceutical composition according to any of the preceding claims wherein the molecule is administered as a dose in a range from about 0.01 mg to about 500 mg, preferably from about 0.1 mg to about 100 mg per day.
Dependencies are inferred from the claim text.